CLINICAL PHARMACOLOGY and THERAPEUTICS

Editor

Walter Modell, M.D.

Associate Editor

Marcus M. Reidenberg, M.D.

Editorial Board

Alvito P. Alvares, Ph.D.
Wilbert S. Aronow, M.D.
Arthur J. Atkinson, Jr., M.D.
Daniel L. Azarnoff, M.D.
Frank M. Berger, M.D., D.Sc.
Karl H. Beyer, Jr., M.D., Ph.D.
Hylan A. Bickerman, M.D.
Terrence F. Blaschke, M.D.
Donald B. Calne, M.D.
Edward A. Carr, Jr., M.D.
Allan H. Conney, Ph.D.
T. S. Danowski, M.D.
Arthur C. DeGraff, M.D.
Edward F. Domino, M.D.
Alvan R. Feinstein, M.D.
Vladimir Fencl, M.D.
Robert B. Forney, Ph.D.
Emil Frei, III, M.D.
Milo Gibaldi, Ph.D.
Leo E. Hollister, M.D.
Bartholomew P. Hsi, Ph.D.
Aryeh Hurwitz, M.D.
Murray E. Jarvik, M.D.
Werner Kalow, M.D.
Stanley A. Kaplan, Ph.D.
Arthur S. Keats, M.D.
Richard H. Kessler, M.D.
Kenneth G. Kohlstaedt, M.D.
Henn Kutt, M.D.
Louis Lasagna, M.D.
Paul S. Leitman, M.D., Ph.D.
Louis Lemberger, M.D., Ph.D.
Gerhard Levy, Pharm.D.
T. A. Loomis, M.D., Ph.D.
David T. Lowenthal, M.D.
Daniel S. Lukas, M.D.
Arno G. Motulsky, M.D.
Alan S. Nies, M.D.
Laurence G. Raisz, M.D.
R. K. Richards, M.D.
David G. Shand, M.B., Ph.D.
Albert Sjoerdsma, M.D., Ph.D.
Jay Tepperman, M.D.
Max Tishler, Ph.D.
Leroy D. Vandam, M.D.
Elliot S. Vesell, M.D.
John G. Wagner, Ph.D.
E. Leong Way, Ph.D.
Louis Weinstein, M.D.

Volume 32, July-December, 1982
The C. V. Mosby Company, St. Louis

Volume 32
Copyright © 1982 by
The C. V. Mosby Company

All rights reserved

Printed in the United States of America

Index to volume 32

Author index

A

Abbrecht PH, O'Leary TJ, Behrendt DM: Evaluation of a computer-assisted method for individualized anticoagulation: retrospective and prospective studies with a pharmacodynamic model, 129

Abel JG, Roth EA, Sellers EM, Ray AK: Drug-plasma protein binding in Kutchin Athapaskan Indians, 436

Abeyasekera G: *see* Brodie et al, 525

Abramson FP: Methadone plasma protein binding: alterations in cancer and displacement from α_1-acid glycoprotein, 652

—Jenkins J, Ostchega Y: Effects of cancer and its treatment on plasma concentration of alpha$_1$-acid glycoprotein and propranolol binding, 659

Adhar G: *see* Duran et al, 554

Affrime MB: *see* Lowenthal et al, 18

—*see* Falkner et al, 577

—*see* Rosenthal et al, 701

Ahmad D: *see* Twum-Barima et al, 289

Aisner J: *see* Egorin et al, 122

Akimoto T: *see* Nomura et al, 303

Alván G: *see* Mellström et al, 664

Ando K: *see* Fujita et al, 366

Andreasen PB: *see* Døssing et al, 392

Andrews-Figueroa P: *see* Velasco et al, 7

Anthonisen NR: *see* Foley et al, 149

Antonello A: *see* Finotti and Antonello, 1

Aranko K: *see* Seppälä et al, 201

Arita T: *see* Nomura et al, 303

Aronoff GR, Ozawa T, DeSante KA, Nash JF, Ridolfo AS: Benoxaprofen kinetics in renal impairment, 190

Aronow WS: *see* Drayer et al, 283

Aspirin Myocardial Infarction Study Research Group: *see* Howard et al, 543

Aurecchia SA: *see* Griffiing et al, 592

B

Bachur NR: *see* Egorin et al, 122

Baker AL: *see* Kotake et al, 261

Barnes JS, Dubocovich ML, Nies AS, Gerber JG: Lack of interaction between tricyclic antidepressants and clonidine at the alpha$_2$-adrenoceptor on human platelets, 744

Bayne W, Place V, Theeuwes F, Rogers JD, Lee RB, Davies RO, Kwan KC: Kinetics of osmotically controlled indomethacin delivery systems after repeated dosing, 270

Beermann B: Kinetics and dynamics of furosemide and slow-acting furosemide, 584

Behrendt DM: *see* Abbrecht et al, 129

Benowitz NL, Kuyt F, Jacob P III: Circadian blood nicotine concentrations during cigarette smoking, 758

Berlinger WG, Goldberg MJ, Spector R, Chiang C-K, Ghoneim MM: Diphenhydramine: kinetics and psychomotor effects in elderly women, 387

Bertilsson L: *see* Mellström et al, 664

Bertoni JM: *see* Casto et al, 628

Bianchine JR, Procter RR, Thomas FB: Piroxicam, aspirin, and gastointestinal blood loss, 247

Bixler EO: *see* Kales et al, 781

Bøjolm S, Paulson OB, Flachs H: Arterial and venous concentrations of phenobarbital, phenytoin, clonazepam, and diazepam after rapid intravenous injections, 478

Bonati M, Latini R, Galletti F, Young JF, Tognoni G, Garattini S: Caffeine disposition after oral doses, 98

Boner G, Wainer E, Rosenfeld JB: Effects of pindolol on renal function II. Effects of intravenous and prolonged oral dosing, 423

Boobis AR: *see* Brodie et al, 525

Boppana VK: *see* Swanson et al, 397

Borch R: *see* Hrushesky et al, 330

Borruso J: *see* Lowenthal et al, 18

Braithwaite R: *see* Dawling et al, 322

Brater DC, Peters MN, Eshelman FN, Richardson CT: Clinical comparison of cimetidine and ranitidine, 484

Brauchi JT: *see* Cherek et al, 253, 765

Breimer DD: *see* Teunissen et al, 240

Brenner M: *see* Szefler et al, 166

Brine DR: *see* Perez-Reyes et al, 635

July, pp. 1-142; August, pp. 143-282; September, pp. 283-406; October, 407-542; November, 543-670; December, 671-810.

Brodie MJ, Boobis AR, Hillyard CJ, Abeyasekera G, Stevenson JC, MacIntyre I, Park BK: Effect of rifampicin and isoniazid on vitamin D metabolism, 525
Burch PG, Stanski DR: Decreased protein binding and thiopental kinetics, 212
Burgess CD: *see* Hames et al, 497
Bustrack JA: *see* Rogers et al, 218
Butz RF: *see* Rogers et al, 218

C

Carr K: *see* Reele et al, 33
Carruthers SG: *see* Twum-Barima et al, 289
Casta A: *see* Singh et al, 607
Casto DT, Ludden TM, Bertoni JM, Littlefield LC, Sagraves RA, Mackey RW: Urine and plasma free phenytoin concentration correlation, 628
Chait LD, Griffiths RR: Smoking behavior and tobacco smoke intake: response of smokers to shortened cigarettes, 90
Cherek DR, Mauroner RF, Brauchi JT: Effects of increasing urinary pH on cigarette smoking, 253
—Smith JE, Lane JD, Brauchi JT: Effects of cigarettes on saliva cortisol levels, 765
Chiang C-K: *see* Berlinger et al, 387
Christensen CK, Pedersen OL, Mikkelsen E: Renal effects of acute calcium blockade with nifedipine in hypertensive patients receiving beta-adrenoceptor–blocking drugs, 572
Cody RJ, Schaer GL, Covit AB, Pondolfino K, Williams G: Captopril kinetics in chronic congestive heart failure, 721
Coelho J: *see* Mullane et al, 692
Coffman JD: *see* Creager et al, 736
Cohen J: *see* Rodman et al, 378
Colvin M: *see* Egorin et al, 122
Comess KA: *see* Fenster et al, 428
Conliffe TF: *see* Foley et al, 149
Conolly ME: *see* Hui et al, 161, 566
Cook CE: *see* Perez-Reyes et al, 459, 635
Cook JD, Lipschitz DA, Skikne BS: Absorption of controlled-release iron, 531
Covit AB: *see* Cody et al, 721
Creager MA, Halperin JL, Klein MD, Coffman JD: Peripheral arterial and venous responses to acetylstrophanthidin in patients with acute myocardial infarction, 736
Cubeddu LX, Zarate NA, Rosales CB, Zschaeck DW: Prazosin and propranolol in preoperative management of pheochromocytoma, 156
Cunningham E, Oliveros FH, Nascimento L: Metolazone therapy of active calcium nephrolithiasis, 642

D

Damiano MD: *see* Kyerematen et al, 769
Davies RO: *see* Bayne et al, 270
—*see* Wilson et al, 676
Davis DD: *see* Phillips et al, 235
Dawling S, Lynn K, Rosser R, Braithwaite R: Nortriptyline metabolism in chronic renal failure: metabolite elimination, 322
DeLia JE, Emery MG, Taylor RH, Scott JR: Flurbiprofen in dysmenorrhea, 76
DeSante KA: *see* Aronoff et al, 190
Desiraju RK: *see* Dromgoole et al, 371
Di Guiseppi S: *see* Perez-Reyes et al, 459, 635
Donaldson RM, Rickards AF: Effect of intravenous amiodarone on myocardial repolarization and refractoriness: a new method of assessment, 727
Dorph-Pedersen A: *see* Pedersen et al, 562
Døssing M: Changes in hepatic microsomal enzyme function in workers exposed to mixtures of chemicals, 340
—Poulsen HE, Andreasen PB, Tygstrup N: A simple method for determination of antipyrine clearance, 392
Drayer DE, Lorenzo B, Lahita RG, Robbins WC, Reidenberg MM: Microsomal hydroxylation as measured by pentobarbital elimination in patients with idiopathic systemic lupus erythematosis, 195
Drayer JIM, Gardin JM, Weber MA, Aronow WS; Changes in ventricular septal thickness during diuretic therapy, 283
Dromgoole SH, Furst DE, Desiraju RK, Nayak RK, Kirshenbaum MA, Paulus HE: Tometin kinetics and synovial fluid prostaglandin E levels in rheumatoid arthritis, 371
Dubocovich ML: *see* Barnes et al, 744
Duchin DL: *see* Singhvi et al, 182
Duran D, Platia EV, Griffith LSC, Adhar G, Reid PR: Suppression of complex ventricular arrhythmias by oral flecainide, 554
Dvorchik BH: *see* Kyerematen et al, 769
Dvornik D: *see* Mullane et al, 692

E

Egorin MJ, Kaplan RS, Salcman M, Aisner J, Colvin M, Wiernik PH, Bachur NR: Cyclophosphamide plasma and cerebrospinal fluid kinetics with and without dimethyl sulfoxide, 122
Elenbaas RM, Ryan JL, Robinson WA, Singsank MJ, Harvey MJ, Klaassen CD: On the disulfiram-like activity of moxalactam, 347
Elliot HL: *see* Sumner et al, 450
Ellis EF: *see* Szefler et al, 166
Elonen E: *see* Neuvonen et al, 25
Emery MG: *see* DeLia et al, 76
Eshelman FN: *see* Brater et al, 484

F

Falkner B, Onesti G, Lowenthal DT, Affrime MB: Effectiveness of centrally acting drugs and diuretics in adolescent hypertension, 577

—*see* Lowenthal et al, 18
—*see* Rosenthal et al, 701
Fand RS: *see* Foley et al, 149
Fenster PE, Comess KA, Hanson CD, Finley PR: Kinetics of the digoxin-aspirin combination, 428
Ferguson RK, Vlasses PH, Swanson BN, Mojaverian P, Hichens M, Irvin JD, Huber PB: Effects of enalapril, a new converting enzyme inhibitor, in hypertension, 48
—*see* Swanson et al, 397
Fields L: *see* Shaw et al, 490
Findlay JWA: *see* Rogers et al, 218
Fink M, Irwin P: Central nervous system effects of aspirin, 362
Finley PR: *see* Fenster et al, 428
Finotti P, Antonello A: Canrenoate reversal of inhibitory effects of digoxin on basal and furosemide-stimulated renin secretion, 1
Firor WB: *see* Wilson et al, 676
Flachs H: *see* Bøjolm et al, 478
Flesher KA: *see* Szefler et al, 166
Foley JE, Sigurdson MJ, Conliffe TF, Fand RS, Anthonisen NR: Effects of cardioselective and nonselective beta-adrenergic antagonists on pulmonary mechanics, 149
Franciosa JA, Silverstein SR: Hemodynamic effects of nitroprusside and furosemide in left ventricular failure, 62
Freis ED: *see* Papademetriou et al, 431
Frölich JC: *see* Reimann et al, 749
Fujita T, Ando K, Sato Y, Yamashita K: Effect of indomethacin on responses to [sar^1-ileu^8]-angiotensin II, 366
Furst DE: *see* Dromgoole et al, 371

G

Gaarder T: *see* Rodman et al, 378
Galletti F: *see* Bonati et al, 98
Garattini S: *see* Bonati et al, 98
Gardin JM: *see* Drayer et al, 283
Gelband H: *see* Singh et al, 607
George CF: *see* Hames et al, 497
Gerber JG: *see* Barnes et al, 744
Ghoneim MM: *see* Berlinger et al, 387
Goldberg MJ: *see* Berlinger et al, 387
Goldstein M: *see* Lieberman et al, 70
Gopinathan G: *see* Lieberman et al, 70
Gorlin R: *see* Packer et al, 54
Gould AB: *see* Lowenthal et al, 18
—*see* Rosenthal et al, 701
Griffing GT, Sindler BH, Aurecchia SA, Melby JC: Temporal enhancement of renin-aldosterone blockade by enalapril, an angiotensin-converting enzyme inhibitor, 592
Griffith LSC: *see* Duran et al, 554
Griffiths RR: *see* Chait and Griffiths, 90
Guevara-Casado J: *see* Velasco et al, 7
Gust SW, Pickens RW: Does cigarette nicotine yield affect puff volume? 418
Györy A: *see* Paulson et al, 466

H

Habedank W-D: *see* Woodcock et al, 622
Halperin JL: *see* Creager et al, 736
Hames TK, Burgess CD, George CF: Hemodynamic responses to trazodone and imipramine, 497
Hamilton JT: *see* Twum-Barima et al, 289
Hammill SC, Shand DG, Herrell FE Jr, Zimmerman JM, Reiter MJ, Verghese C, Pritchett ELC: Pirmenol kinetics and effective oral dose, 686
Hanson CD: *see* Fenster et al, 428
Harrell FE Jr: *see* Hammill et al, 686
Harvey MJ: *see* Elenbaas et al, 347
Hernández E: *see* Velasco et al, 7
Hernández-Pieretti O: *see* Velasco et al, 7
Hertz MM: *see* Paulson et al, 466
Hichens M: *see* Ferguson et al, 48
Higgins JT: *see* Somani et al, 113
Hillyard CJ: *see* Brodie et al, 525
Hollister LE: *see* Mellar and Hollister, 671
Holmes GI: *see* Swanson et al, 397
—*see* Wilson et al, 676
Hoover JJ: *see* Howard et al, 543
Hoppe-Seyler G: *see* Keller et al, 442
Howard J, Whittemore AS, Hoover JJ, Panos M, Aspirin Myocardial Infarction Study Research Group: How blind was the patient blind in AMIS? 543 (Commentary)
Hrushesky WJM, Borch R, Levi F: Circadian time dependence of cisplatin urinary kinetics, 330
Huber PB: *see* Ferguson et al, 48
—*see* Wilson et al, 676
Hui KK, Wolfe RN, Conolly ME: Lymphocyte beta-adrenergic receptors are not altered in hyperthyroidism, 161
Hui KKP, Conolly ME, Tashkin DP: Reversal of human lymphocyte beta-adrenoceptor desensitization of glucocorticoids, 566
Hull JH: *see* Rogers et al, 218
Hurst A: *see* Rodman et al, 378
Hvidt S: *see* Pedersen et al, 562

I

Idle JR: *see* Oates et al, 81
Insel T: *see* Linnoila et al, 208
Irvin JD: *see* Ferguson et al, 48
Irwin P: *see* Fink and Irwin, 362

J

Jackson PR, Tucker GT, Woods HF: Altered plasma drug binding in cancer: role of α_1-acid glycoprotein and albumin, 295
Jacob P III: *see* Benowitz et al, 758
Jacoby J: *see* Kales et al, 781
Jeffcoat AR: *see* Perez-Reyes et al, 459
Jelliffe RW: *see* Rodman et al, 378
Jenkins J: *see* Abramson et al, 659
Johnson GE: *see* Wilson et al, 676

Jones EC: *see* Rogers et al, 218
Josephs H: *see* Kotake et al, 261
Jusko WJ: *see* Szefler et al, 166

K

Kales A, Bixler EO, Soldato CR, Vela-Bueno A, Jacoby J, Kales JD: Quazepam and flurazepam: long-term use and extended withdrawal, 781
Kales JD: *see* Kales et al, 781
Kaplan RS: *see* Egorin et al, 122
Katoh K: *see* Nomura et al, 303
Kaufman J: *see* Mullane et al, 692
Keller E, Hoppe-Seyler G, Schollmeyer P: Disposition and diuretic effect of furosemide in the nephrotic syndrome, 442
Kelvie W: *see* Sriwatanakul et al, 143
Kessler K: *see* Singh et al, 607
Khatri IM: *see* Papademetriou et al, 431
Kierulf P: *see* Pike et al, 599
Kilts C: *see* Linnoila et al, 208
Kirschenbaum MA: *see* Dromgoole et al, 371
Kjær K: *see* Pedersen et al, 562
Klaassen CD: *see* Elenbaas et al, 347
Klein MD: *see* Creager et al, 736
Kley HK, Müller A, Peerenboom H, Krüskemper HL: Digoxin does not alter plasma steroid levels in healthy men, 12
Klitgaard NA: *see* Pedersen et al, 562
Klotz U, Ziegler G: Physiologic and temporal variation in hepatic elimination of midazolam, 107
—*see* Reimann et al, 749
Kornhauser D: *see* Reele et al, 33
Kotake AN, Schoeller DA, Lambert GH, Baker AL, Schaffer DD, Josephs H: The caffeine CO_2 breath test: dose response and route of *N*-demethylation in smokers and nonsmokers, 261
Krüskemper HL: *see* Kley et al, 12
Kuhlmann J, Wilke J, Rietbrock N: Cytostatic drugs are without significant effect on digitoxin plasma level and renal excretion, 646
Kuyt F: *see* Benowitz et al, 758
Kwan KC: *see* Bayne et al, 270
Kyerematen GA, Damiano MD, Dvorchik BH, Vesell ES: Smoking-induced changes in nicotine disposition: application of a new HPLC assay for nicotine and its metabolites, 769

L

Lahita RG: *see* Drayer et al, 195
Lambert GH: *see* Kotake et al, 261
Lane JD: *see* Cherek et al, 765
Lasagna L: *see* Sriwatanakul et al, 143
Latini R: *see* Bonati et al, 98
Lee KL: *see* Phillips et al, 235
Lee RB: *see* Bayne et al, 270
Leibowitz M: *see* Lieberman et al, 70
Levi F: *see* Hrushesky et al, 330
Levy G: *see* Whitfield et al, 503
Lieberman AN, Goldstein M, Neophytides A, Leibowitz M, Gopinathan G, Walker R, Pact V: The use of pergolide, a potent dopamine agonist, in Parkinson's disease, 70
Lindström B: *see* von Bahr et al, 41
Linnoila M, Insel T, Kilts C, Potter WZ, Murphy DL: Plasma steady-state concentrations of hydroxylated metabolites of clomipramine, 208
Lipschitz DA: *see* Cook et al, 531
Littlefield LC: *see* Casto et al, 628
Loh W: *see* Woodcock et al, 622
Lorenzo B: *see* Drayer et al, 195
Lowenthal DT, Affrime MB, Rosenthal L, Gould AB, Borruso J, Falkner B: Dynamic and biochemical responses to single and repeated doses of clonidine during dynamic physical activity, 18
—*see* Falkner et al, 577
—*see* Rosenthal et al, 701
Ludden TM: *see* Casto et al, 628
Lunde PKM: *see* Pike et al, 599
Lunn J: *see* Moser and Lunn, 307
Lynn K: *see* Dawling et al, 322

M

MacIntyre I: *see* Brodie et al, 525
Mackey RW: *see* Casto et al, 628
McKinstry DN: *see* Singhvi et al, 182
Mattila MJ: *see* Seppälä et al, 201
Mauroner RF: *see* Cherek et al, 253
May MS: *see* Wardell et al, 407
Mayock R: *see* Shaw et al, 490
Medina N: *see* Packer et al, 54
Mehta AV: *see* Singh et al, 607
Melby JC: *see* Griffing et al, 592
Mellar J, Hollister LE: Phenmetrazine: an obsolete problem drug, 671
Meller J: *see* Packer et al, 54
Mellström B, Alván G, Bertilsson L, Potter WZ, Säwe J, Sjöqvist F: Nortriptyline formation after single oral and intravenous doses of amitriptyline, 664
Migdalof BH: *see* Singhvi et al, 182
Mikkelsen E: *see* Christensen et al, 572
Miyazaki K: *see* Nomura et al, 303
Mojaverian P: *see* Ferguson et al, 48
Monsell K: *see* Swanson et al, 397
Morris KG: *see* Phillips et al, 235
Moser M, Lunn J: Responses to captopril and hydrochlorothiazide in black patients with hypertension, 307
Mullane JF, Kaufman J, Dvornik D, Coelho J: Propranolol dosage, plasma concentration, and beta blockade, 692
Müller A: *see* Kley et al, 12
Murphy DL: *see* Linnoila et al, 208

N

Nascimento L: *see* Cunningham et al, 642
Nash JF: *see* Aronoff et al, 190
Nayak RK: *see* Dromgoole et al, 371
Neophytides A: *see* Lieberman et al, 70
Neuvonen PJ, Elonen E, Tanskanen A, Tuomilehto J: Sotalol prolongation of the QT_c interval in hypertensive patients, 25
Nielson-Kudsk F: *see* Pedersen et al, 562
Nies AS: *see* Barnes et al, 744
—*see* Woosley et al, 313
Nieves D: *see* Velasco et al, 7
Nomura A, Yasuda H, Katoh K, Akimoto T, Miyazaki K, Arita T: Hydralazine and furosemide kinetics, 303
Notargiacomo AV: *see* Papademetriou et al, 431

O

Oates JA: *see* Reele et al, 33
—*see* Woosley et al, 313
Oates NS, Shah RR, Idle JR, Smith RL: Genetic polymorphism of phenformin 4-hydroxylation, 81
Okun R: Analgesic effects of oral nalbuphine and codeine in patients with postoperative pain, 517
O'Leary TJ: *see* Abbrecht et al, 129
Oliveros FH: *see* Cunningham et al, 642
Ondrusek G: *see* Perez-Reyes et al, 459
Onesti G: *see* Falkner et al, 577
O'Reilly RA: Ticrynafen-racemic warfarin interaction: hepatotoxic or stereoselective, 356
Ostchega Y: *see* Abramson et al, 659
Ozawa T: *see* Aronoff et al, 190

P

Packer M, Gorlin R, Meller J, Medina N: Central hemodynamic effects of dipyridamole in severe heart failure: comparison with hydralazine, 54
Pact V: *see* Lieberman et al, 70
Panos M: *see* Hoover et al, 543
Papademetriou V, Notargiacomo AV, Khatri IM, Freis ED: Treatment of severe hypertension with intravenous labetolol, 431
Park BK: *see* Brodie et al, 525
Paulson OB, Györy A, Hertz MM: Blood-brain barrier transfer and cerebral uptake of antiepiliptic drugs, 466
—*see* Bøjolm et al, 478
Paulus HE: *see* Dromgoole et al, 371
Pedersen KE, Dorph-Pedersen A, Hvidt S, Klitgaard NA, Kjær K, Nielson-Kudsk F: Effect of nifedipine on digoxin kinetics in healthy subjects, 562
Pedersen OL: *see* Christensen et al, 572
Peerenboom H: *see* Kley et al, 12
Perez-Reyes M, Di Guiseppi S, Brine DR, Smith H, Cook CE: Urine pH and phencyclidine excretion, 635
—, —, Ondrusek G, Jeffcoat AR, Cook CE: Free-base cocaine smoking, 459
Peters MN: *see* Brater et al, 484
Phillips HR, Stack RS, Davis DD, Morris KG, Lee KL, Shand DG, Pritchett ELC: Hemodynamic effects of the antiarrhythmic drug pirmenol, 235
Pickens RW: *see* Gust and Pickens, 418
Pickoff AS: *see* Singh et al, 607
Pike E, Skuterud B: Plasma binding variations of amitriptyline and nortriptyline, 228
—, —, Kierulf P, Lunde PKM: Significance of lipoproteins in serum binding variations of amitriptyline, nortriptyline, and quinidine, 599
Place V: *see* Bayne et al, 270
Platia EV: *see* Duran et al, 554
Pondolfino K: *see* Cody et al, 721
Potter WZ: *see* Linnoila et al, 208
—*see* Mellström et al, 664
Poulsen HE: *see* Døssing et al, 392
Pritchett ELC: *see* Hammill et al, 686
—*see* Phillips et al, 235
—*see* Reiter et al, 711
Procter RR: *see* Bianchine et al, 247

R

Ray AK: *see* Abel et al, 436
Reele SB, Kornhauser D, Shand D, Carr K, Oates JA, Woosley RL: Antiarrhythmic effects of the quaternary propranolol analog that does not induced beta-adrenergic blockade, 33
—*see* Woosley et al, 313
Reid JL: *see* Sumner et al, 450
Reid PR: *see* Duran et al, 554
Reidenberg MM: *see* Drayer et al, 195
Reimann IW, Klotz U, Frölich JC: Effects of cimetidine and ranitidine on steady-state propranolol kinetics and dynamics, 749
Reiter C, Weinshilboum R: Platelet phenol sulfotransferase activity: correlation with sulfate conjugation of acetaminophen, 612
Reiter MJ, Shand DG, Pritchett ELC: Comparison of intravenous and oral verapamil dosing, 711
—*see* Hammill et al, 686
Richardson CT: *see* Brater et al, 484
Rickards AF: *see* Donaldson and Rickards, 727
Ridolfo AS: *see* Aronoff et al, 190
Rietbrock N: *see* Kuhlmann et al, 646
—*see* Woodcock et al, 622
Robbins WC: *see* Drayer et al, 195
Robinson WA: *see* Elenbaas et al, 347
Rocchini AP: *see* Wagner et al, 172
Roden DM: *see* Woosley et al, 313
Rodman JH, Hurst A, Gaarder T, Cohen J, Jelliffe RW: *N*-Acetylprocainimide kinetics and clinical response during repeated dosing, 378

Rogers JD: *see* Bayne et al, 270
Rogers JF, Findlay JWA, Hull JH, Butz RF, Jones EC, Bustrack JA, Welch RM: Codeine disposition in smokers and nonsmokers, 218
Rosales CB: *see* Cubeddu et al, 156
Rosenfeld JB: *see* Boner et al, 423
Rosenthal L, Affrime MB, Lowenthal DT, Falkner B, Saris S, Gould AB: Biochemical and dynamic responses to single and repeated doses of methyldopa and propranolol during dynamic physical activity, 701
—*see* Lowenthal et al, 18
Rosser R: *see* Dawling et al, 322
Roth EA: *see* Abel et al, 436
Ryan JL: *see* Elenbaas et al, 347

S

Sagraves RA: *see* Casto et al, 628
Saris S: *see* Rosenthal et al, 701
Sato Y: *see* Fujita et al, 366
Säwe J: *see* Mellström et al, 664
Schaer GL: *see* Cody et al, 721
Schaffer DD: *see* Kotake et al, 261
Schentag JJ: *see* Whitfield et al, 503
Schoeller DA: *see* Kotake et al, 261
Schollmeyer P: *see* Keller et al, 442
Scott JR: *see* DeLia et al, 76
Seideman P: *see* von Bahr et al, 41
Sellers EM: *see* Abel et al, 436
Seppälä T, Aranko K, Mattila MJ, Shrotriya RC: Effects of alcohol on buspirone and lorazepam actions, 201
Shah RR: *see* Oates et al, 81
Shand D: *see* Reele et al, 33
Shand DG: *see* Hammill et al, 686
—*see* Phillips et al, 235
—*see* Reiter et al, 711
Shapiro RS: *see* Somani et al, 113
Shaw LM, Fields L, Mayock R: Factors influencing theophylline serum protein binding, 490
Shrotriya RC: *see* Seppälä et al, 201
Sigurdson MJ: *see* Foley et al, 149
Silverstein SR: *see* Franciosa and Silverstein, 62
Sindler BH: *see* Griffing et al, 592
Singh S, Gelband H, Mehta AV, Kessler K, Casta A, Pickoff AS: Procainamide elimination kinetics in pediatric patients, 607
Singhvi SM, Duchin KL, Willard DA, McKinstry DN, Migdalof BH: Renal handling of captopril: effect of probenecid, 182
Singsank MJ: *see* Elenbaas et al, 347
Sjöqvist F: *see* Mellström et al, 664
Skikne BS: *see* Cook et al, 531
Skuterud B: *see* Pike et al, 599
—*see* Pike and Skuterud, 228
Slacman M: *see* Egorin et al, 122
Smith H: *see* Perez-Reyes et al, 635
Smith JE: *see* Cherek et al, 765
Smith RL: *see* Oates et al, 81
Soldato CR: *see* Kales et al, 781
Somani P, Shapiro RS, Stockard H, Higgins JT: Unidirectional absorption of gentamicin from the peritoneum during continuous ambulatory peritoneal dialysis, 113
Spector R: *see* Berlinger et al, 387
Spector SL: *see* Szefler et al, 166
Srivastava AK: *see* Teunissen et al, 240
Sriwatanakul K, Kelvie W, Lasagna L: The quantification of pain: an analysis of words used to describe pain and analgesia in clinical trials, 143 (Commentary)
Stack RS: *see* Phillips et al, 235
Stanski DR: *see* Burch and Stanski, 212
Stevenson JC: *see* Brodie et al, 525
Stockard H: *see* Somani et al, 113
Sumner DJ, Elliot HL, Reid JL: Analysis of the pressor dose response, 450
Swanson BN, Boppana VK, Vlasses PH, Holmes GI, Monsell K, Ferguson RK: Sulindac disposition when given once and twice daily, 397
—*see* Ferguson et al, 48
Szefler SJ, Brenner M, Jusko WJ, Spector SL, Flesher KA, Ellis EF: Dose- and time-related effect of troleandomycin on methylprednisolone elimination, 166

T

Tanskanen A: *see* Neuvonen et al, 25
Tashkin DP: *see* Hui et al, 566
Taylor RH: *see* DeLia et al, 76
Teunissen MWE, Srivastava AK, Breimer DD: Influence of sex and oral contraceptive steroids on antipyrine metabolite formation, 240
Theeuwes F: *see* Bayne et al, 270
Thomas FB: *see* Bianchine et al, 247
Tognoni G: *see* Bonati et al, 98
Trimble AG: *see* Wardell et al, 407
Tsianco MC: *see* Wilson et al, 676
Tucker GT: *see* Jackson et al, 295
Tuomilehto J: *see* Neuvonen et al, 25
Twum-Barima Y, Ahmad D, Hamilton JT, Carruthers SG: Ineffectiveness of beta-adrenergic blockers on ventilatory response to carbon dioxide, 289
Tygstrup N: *see* Døssing et al, 392

U

Urbina-Quintana A: *see* Velasco et al, 7

V

Vasiliades J: *see* Wagner et al, 172
Vela-Bueno A: *see* Bales et al, 781
Velasco M, Urbina-Quintana A, Andrews-Figueroa P, Nieves D, Hernández E, Guevara-Casado J, Hernández-Pieretti O: Effect of indoramin and propranolol on cardiovascular response to cold in hypertensive patients, 7

Verghese C: *see* Hammill et al, 686
Vesell ES: *see* Kyerematen et al, 769
Vlasses PH: *see* Ferguson et al, 48
—*see* Swanson et al, 397
Von Bahr C, Lindström B, Seideman P: α-Receptor function changes after the first dose of prazosin, 41

W

Wagner JG, Rocchini AP, Vasiliades J: Prediction of steady-state verapamil plasma concentrations in children and adults, 172
Wainer E: *see* Boner et al, 423
Walker R: *see* Lieberman et al, 70
Wardell WM, May MS, Trimble AG: New drug development by United States pharmaceutical firms, with analysis of trends in the acquisition and origin of drug candidates, 1963-1979, 407 (Commentary)
Weber MA: *see* Drayer et al, 283
Weinshilboum R: *see* Reiter and Weinshilboum, 612
Welch RM: *see* Rogers et al, 218
Whitfield LR, Schentag JJ, Levy G: Relationship between concentration and anticoagulant effect of heparin in plasma of hospitalized patients: magnitude and predictability of interindividual differences, 503
Whittemore AS: *see* Howard et al, 543
Wiernik P: *see* Egorin et al, 122
Wilke J: *see* Kuhlmann et al, 646
Willard DA: *see* Singhvi et al, 182
Williams G: *see* Cody et al, 721
Wilson TW, Firor WB, Johnson GE, Holmes GI, Tsianco MC, Huber PB, Davies RO: Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade, 676
Wolfe RN: *see* Hui et al, 161
Woodcock BG, Loh W, Habedank W-D, Rietbrock N: Dihydroergotoxine kinetics in healthy men after intravenous and oral administration, 622
Woods HF: *see* Jackson et al, 295
Woosley RL, Reele SB, Roden DM, Nies AS, Oates JA: Pharmacologic reversal of hypotensive effect complicating antiarrhythmic therapy with bretylium, 313
—*see* Reele et al, 33

Y

Yamashita K: *see* Fujita et al, 366
Yasuda H: *see* Nomura et al, 303
Young JF: *see* Bonati et al, 98

Z

Zarate NA: *see* Cubeddu et al, 156
Ziegler G: *see* Klotz and Ziegler, 107
Zimmerman JM: *see* Hammill et al, 686
Zschaeck DW: *see* Cubeddu et al, 156

Subject index

A

Absorption, unidirectional, of gentamicin from the peritoneum during continuous ambulatory peritoneal dialysis (Somani et al), 113
Acetaminophen, sulfate conjugation of, correlation with: platelet phenol sulfotransferase activity (Reiter and Weinshilboum), 612
N-Acetylprocainamide kinetics and clinical response during repeated dosing (Rodman et al), 378
Acetylstrophanthidin, peripheral arterial and venous responses to, in patients with acute myocardial infarction (Creager et al), 736
Acid glycoprotein, α_1-, and albumin, role of: altered plasma drug binding in cancer (Jackson et al), 295
  displacement from and alterations in cancer: methadone plasma protein binding (Abramson), 652
  plasma concentration of, and propranolol binding, effects of cancer and its treatments on (Abramson et al), 659
Acodazole hydrochloride (USAN list No. 231), 789
Acquisition and origin of drug candidates, 1963-1979, with analysis of new drug development by United States pharmaceutical firms (Wardell et al), 407
Adolescent hypertension, effectiveness of centrally acting drugs and diuretics in (Falkner et al), 577

July, pp. 1-142; August, pp. 143-282; September, pp. 283-406; October, pp. 407-542; November, pp. 543-670; December, pp. 671-810.

Adrenergic antagonists, beta-, cardioselective and nonselective, effects of on pulmonary mechanics (Foley et al), 149
blockade, beta-, antiarrhythmic effects of quarternary propranolol analog that does not induce (Reele et al), 33
blockers, beta-, ineffectiveness of, on ventilatory response to carbon dioxide (Twum-Barima et al), 289
receptors, beta-, lymphocyte, are not altered in hyperthyroidism (Hui et al), 161
Adrenoceptor, alpha$_2$-, on human platelets, lack of interaction between tricyclic antidepressants and clonidine at the (Barnes et al), 744
beta-, desensitization of glucocorticoids, reversal of human lymphocyte (Hui et al), 566
–blocking drugs, beta-, hypertensive patients receiving, renal effects of acute calcium blockade with nifedipine in (Christensen et al), 572
Adults and children, prediction of steady-state verapamil concentrations in (Wagner et al), 172
Albumin and α_1-acid glycoprotein, role of: altered plasma drug binding in cancer (Jackson et al), 295
Alcohol, effect of, on buspirone and lorazepam actions (Seppälä et al), 201
Alfaprostol (USAN list No. 229), 541
Alpha$_2$-adrenoceptor on human platelets, lack of interaction between tricyclic antidepressants and clonidine at the (Barnes et al), 744
Alpha-receptor function changes after first dose of prazosin (von Bahr et al), 41
Ambulatory peritoneal dialysis, continuous, unidirectional absorption of gentamicin from the peritoneum during (Somani et al), 113
American Society for Clinical Pharmacology and Therapeutics, notes of, 139, 279, 406, 542, 791
Amiodarone, intravenous, effects of, on myocardial repolarization and refractoriness: a new method of assessment (Donaldson and Rickards), 727
AMIS, how blind was the patient blind in (Howard et al), 543 (Commentary)
Amitriptyline, nortriptyline formation after single oral and intravenous doses of (Mellström et al), 664
plasma binding variations of (Pike and Skuterud), 228
and quinidine, significance of lipoproteins in serum binding variations of (Pike et al), 599
Analgesia and pain in clinical trials, an analysis of words used to describe: quantification of pain (Sriwatanakul et al), 143 (Commentary)
Analgesic effects of oral nalbuphine and codeine in patient with postoperative pain (Okun), 517
Angiotensin-converting enzyme inhibitor, enalapril, temporal enhancement of renin-aldosterone blockade by (Griffing et al), 592
II, [sar^1-ileu^8]-, effect of indomethacin on responses to (Fujita et al), 366
Aniracetam (USAN list No. 226), 137
Antiarrhythmic drug pirmenol, hemodynamic effects of (Phillips et al), 235
effects of quarternary propranolol analog that does not induce beta-adrenergic blockade (Reele et al), 33
therapy with bretylium, pharmacologic reversal of hypotensive effect complicating (Woosley et al), 313
Anticoagulant effect of heparin, relationship between concentration and, in plasma of hospitalized patients: magnitude and predictability of interindividual differences (Whitfield et al), 503
Anticoagulation, individualized, evaluation of a computer-assisted method for: retrospective and prospective studies with a pharmacodynamic model (Abbrecht et al), 129
Antidepressants, tricyclic, and clonidine, lack of interaction between, at the alpha$_2$-adrenoceptor on human platelets (Barnes et al), 744
Antiepileptic drugs, cerebral uptake of, blood-brain barrier transfer and (Paulson et al), 466
Antipyrine clearance, a simple method for determination of (Døssing et al), 392
metabolite formation, influence of sex and contraceptive oral steroids on (Teunissen et al), 240
Arrhythmias, venticular, complex, suppression of, by oral flecainide (Duran et al), 554
Arterial and venous concentrations of phenobarbital, phenytoin, clonazepam, and diazepam after rapid intravenous injection (Bøjolm et al), 478
responses, peripheral, to acetylstrophanthidin in patients with acute myocardial infarction (Creager et al), 736
Arthritis, rheumatoid, tolmetin kinetics and synovial fluid prostaglandin E levels in (Dromgoole et al), 371
Aspirin, central nervous system effects of (Fink and Irwin), 362
-digoxin combination, kinetics of (Fenster et al), 428
piroxicam, and gastointestinal blood loss (Bianchine et al), 247
Athapaskan Indians, Kutchin, drug-plasma protein binding in (Abel et al), 436
Azaconazole (USAN list No. 226), 137

B

Basal and furosemide-stimulated renin secretion, canrenoate reversal of inhibitory effects of digoxin on (Finotti and Antonello), 1
Benoxaprofen kinetics in renal impairment (Aronoff et al), 190
Beta-adrenergic antagonists, cardioselective and nonselective, effects of on pulmonary mechanics (Foley et al), 149
blockade, antiarrhythmic effects of quarternary propranolol analog that does not induce (Reele et al), 33
blockers, ineffectiveness of, on ventilatory response to carbon dioxide (Twum-Barima et al), 289
receptors, lymphocyte, are not altered in hyperthyroidism (Hui et al), 161
Beta-adrenoceptor–blocking drugs, hypertensive patients receiving, renal effects of acute calcium blockade with nifedipine in (Christensen et al), 572
desensitization of glucocorticoids, reversal of human lymphocyte (Hui et al), 566
Beta blockade, bioavailability, and plasma concentrations: timolol and propranolol (Wilson et al), 676
plasma concentration, and propranolol dosage (Mullane et al), 692
Bifonazole (USAN list No. 228), 404
Binding, altered plasma drug, in cancer: role of α_1-acid glycoprotein and albumin (Jackson et al), 295
drug-plasma protein, in Kutchin Athapaskan Indians (Abel et al), 436
plasma, variations of amitriptyline and nortriptyline (Pike and Skuterud), 228
propranolol, and plasma concentration of alpha$_1$-acid glycoprotein, effects of cancer and its treatments on (Abramson et al), 659
protein, decreased, and thiopental kinetics (Burch and Stanski), 212
theophylline serum protein, factors influencing (Shaw et al), 490
variations, serum, significance of lipoproteins in, of amitriptyline, nortriptyline, and quinidine (Pike et al), 599
Bioavailability, plasma concentrations, and beta blockade: timolol and propranolol (Wilson et al), 676
Biochemical and dynamic responses to single and repeated doses of methyldopa and propranolol during dynamic physical activity (Rosenthal et al), 701
Black patients with hypertension, responses to captopril and hydrochlorothiazide in (Moser and Lunn), 307
Blockade, acute calcium, renal effects of, with nifedipine in hypertensive patients receiving beta-adrenoceptor–blocking drugs (Christensen et al), 572
Blockade—cont'd
beta-adrenergic, antiarrhythmic effects of quarternary propranolol analog that does not induce (Reele et al), 33
beta, bioavailability, and plasma concentrations: timolol and propranolol (Wilson et al), 676
plasma concentration, and propranolol dosage (Mullane et al), 692
renin-aldosterone, by enalapril, an angiotensin-converting enzyme inhibitor, temporal enhancement of (Griffing et al), 592
Blockers, beta-adrenergic, ineffectiveness of, on ventilatory response to carbon dioxide (Twum-Barima et al), 289
Blood-brain barrier transfer and cerebral uptake of antiepileptic drugs (Paulson et al), 466
nicotine concentrations, circadian, during cigarette smoking (Benowitz et al), 758
Brain-blood barrier transfer and cerebral uptake of antiepileptic drugs (Paulson et al), 466
Breath test, caffeine CO_2; dose response and route of *N*-demethylation in smokers and nonsmokers (Kotake et al), 261
Bretylium, antiarrhythmic therapy with, pharmacologic reversal of hypotensive effect complicating (Woosley et al), 313
Buspirone and lorazepam actions, effects of alcohol on (Seppälä et al), 201
Butixirate (USAN list No. 229), 541

C

Caffeine CO_2 breath test: dose response and route of *N*-demethylation in smokers and nonsmokers (Kotake et al), 261
disposition after oral doses (Bonati et al), 98
Calcium blockade, acute, renal effects of, with nifedipine in hypertensive patients receiving beta-adrenoceptor–blocking drugs (Christensen et al), 572
nephrolithiasis, active, metolazone therapy of (Cunningham et al), 642
Cancer, alterations in, and displacement from α_1-acid glycoprotein: methadone plasma protein binding (Abramson), 652
altered plasma drug binding in: role of α_1-acid glycoprotein and albumin (Jackson et al), 295
and its treatments, effects of, on plasma concentration of alpha$_1$-acid glycoprotein and propranolol binding (Abramson et al), 659
Canrenoate reversal of inhibitory effects of digoxin on basal and furosemide-stimulated renin secretion (Finotti and Antonello), 1
Captopril and hydrochlorothiazide, responses to, in black patients with hypertension (Moser and Lunn), 307
kinetics in chronic congestive heart failure (Cody et al), 721
renal handling of: effect of probenecid (Singhvi et al), 182

Carbon dioxide, ventilatory response to, ineffectiveness of beta-adrenergic blockers on (Twum-Barima et al), 289
Cardioselective and nonselective beta-adrenergic antagonists, effects of on pulmonary mechanics (Foley et al), 149
Cardiovascular response to cold, effects of indoramin and propranolol on, in hypertensive patients (Velasco et al), 7
Central nervous system effects of aspirin (Fink and Irwin), 362
Cerebral uptake of antiepileptic drugs, blood-brain barrier transfer and (Paulson et al), 466
Cetraxate hydrochloride (USAN list No. 230), 669
Children and adults, prediction of steady-state verapamil concentrations in (Wagner et al), 172
Cigarette(s), effects of, on saliva cortisol levels (Cherek et al), 765
nicotine yield, does it affect puff volume? (Gust and Pickens), 418
shortened, response of smokers to: smoking behavior and tobacco smoke intake (Chait and Griffiths), 90
smoking, circadian blood nicotine concentrations during (Benowitz et al), 758
effects of increasing urinary pH on (Cherek et al), 253
Cimetidine and ranitidine, clinical comparison of (Brater et al), 484
effects of, on steady-state propranolol kinetics and dynamics (Reimann et al), 749
Circadian blood nicotine concentrations during cigarette smoking (Benowitz et al), 758
time dependence of cisplatin urinary kinetics (Hrushesky et al), 330
Cisplatin urinary kinetics, circadian time dependence of (Hrushesky et al), 330
Clearance, antipyrine, a simple method for determination of (Døssing et al), 392
Clinical Pharmacology and Therapeutics, American Society: *see* American Society for Clinical Pharmacology and Therapeutics
Clomipramine, plasma steady-state concentrations of hydroxylated metabolites of (Linnoila et al), 208
Clonazepam, phenytoin, phenobarbital, and diazepam, arterial and venous concentrations of, after rapid intravenous injection (Bøjolm et al), 478
Clonidine, dynamic and biochemical responses to single and repeated doses of, during dynamic physical activity (Lowenthal et al), 18
and tricyclic antidepressants, lack of interaction between, at the alpha$_2$-adrenoceptor on human platelets (Barnes et al), 744
CO_2 breath test, caffeine: dose response and route of *N*-demethylation in smokers and nonsmokers (Kotake et al), 261
Cocaine smoking, free-base (Perez-Reyes et al), 459
Codeine disposition in smokers and nonsmokers (Rogers et al), 218
and nalbuphine, oral, analgesic effects of in patients with postoperative pain (Okun), 517
Cold, cardiovascular response to, effects of indoramine and propranolol on, in hypertensive patients (Velasco et al), 7
Computer-assisted method, evaluation of, for individualized anticoagulation: retrospective and prospective studies with a pharmacodynamic model (Abbrecht et al), 129
Congestive heart failure, chronic, captopril kinetics in (Cody et al), 721
Controlled-release iron, absorption of (Cook et al), 531
Converting enzyme inhibitor, a new, effects of enalapril in hypertension (Ferguson et al), 48
Cortisol levels, saliva, effects of cigarettes on (Cherek et al), 765
Cromitrile sodium (USAN list No. 228), 404
Croscarmellose sodium (USAN list No. 228), 405
Cyclophosphamide plasma and cerebrospinal fluid kinetics with and without dimethyl sulfoxide (Egorin et al), 122
Cytostatic drugs are without significant effect on digitoxin plasma level and renal excretion (Kuhlmann et al), 646

D

Delivery systems, indomethacin, kinetics of osmotically controlled, after repeated dosing (Bayne et al), 270
N-Demethylation, dose response and route of, in smokers and nonsmokers: caffeine CO_2 breath test (Kotake et al), 261
Dialysis, continuous ambulatory peritoneal, unidirectional absorption of gentamicin from the peritoneum during (Somani et al), 113
Diazepam, phenobarbital, phenytoin, and clonazepam, arterial and venous concentrations of, after rapid intravenous injection (Bøjolm et al), 478
Diaziquone (USAN list No. 228), 405
Digitoxin plasma level and renal excretion, cytostatic drugs are without significant effect on (Kuhlmann et al), 646
Digoxin does not alter plasma steroid levels in healthy men (Kley et al), 12
-aspirin combination, kinetics of (Fenster et al), 428
canrenoate reversal of inhibitory effects of, on basal and furosemide-stimulated renin secretion (Finotti and Antonello), 1
kinetics in healthy subjects, effect of nifedipine on (Pedersen et al), 562
Dihydroergotoxine kinetics in healthy men after intravenous and oral administration (Woodcock et al), 622
Dimethyl sulfoxide, cyclophosphamide plasma and cerebrospinal fluid kinetics with and without (Egorin et al), 122

Diphenhydramine: kinetics and psychomotor effects in elderly women (Berlinger et al), 387
Dipyridamole in severe heart failure, central hemodynamic effects of: comparison with hydralazine (Packer et al), 54
Disposition: *see* specific drug
Disulfiram-like activity of moxalactam (Elenbaas et al), 347
Diuretic(s) and centrally acting drugs, effectiveness of, in adolescent hypertension (Falkner et al), 577
effect and disposition of furosemide in the nephrotic syndrome (Keller et al), 442
therapy, ventricular septal thickness during (Drayer et al), 283
Dopamine agonist, a potent, pergolide, use of in Parkinson's disease (Lieberman et al), 70
Dose response, pressor, analysis of (Sumner et al), 450
and time-related effect of troleandomycin on methylprednisolone elimination (Szefler et al), 166
Drug(s): *see also* specific
Drug development, new, by United States pharmaceutical firms, with analysis of trends in the acquisition and origin of drug candidates, 1963-1979 (Wardell et al), 407
Dynamic physical activity, dynamic and biochemical responses of single and repeated doses of clonidine during (Lowenthal et al), 18
Dysmenorrhea, flurbiprofen in (DeLia et al), 76

E

Edetate dipotassium (USAN list No. 229), 540
Elderly women, kinetics and psychomotor effects of diphenhydramine in (Berlinger et al), 387
Elimination: *see* specific drug name
Enalapril, an angiotensin-converting enzyme inhibitor, temporal enhancement of renin-aldosterone blockade by (Griffing et al), 592
a new converting enzyme inhibitor, effects of in hypertension (Ferguson et al), 48
Enzyme function, hepatic microsomal, changes in, in workers exposed to mixtures of chemicals (Døssing), 340
inhibitor, angiotensin-converting, enalapril, temporal enhancement of renin-aldosterone blockade by (Griffing et al), 592
a new converting, effects of enalapril in hypertension (Ferguson et al), 48
Esterifilcon A (USAN list No. 230), 669

F

Fenprinast hydrochloride (USAN list No. 229), 541
Flecainide, oral, suppression of complex ventricular arrhythmias by (Duran et al), 554
Fludarabine phosphate (USAN list No. 230), 668
Fluradoline hydrochloride (USAN list No. 231), 790
Flurazepam and quazepam: long-term use and extended withdrawal (Kales et al), 781
Flurbiprofen in dysmenorrhea (DeLia et al), 76
Free-base cocaine smoking (Perez-Reyes et al), 459
Furosemide, disposition and diuretic effect of, in nephrotic syndrome (Keller et al), 442
and hydralazine kinetics (Nomura et al), 303
and nitroprusside, hemodynamic effects of, in left ventricular failure (Franciosa et al), 62
and slow-acting furosemide, kinetics and dynamics of (Beerman), 584
-stimulated and basal renin secretion, canrenoate reversal of inhibitory effects of digoxin on (Finotti and Antonello), 1

G

Gastrointestinal blood loss and piroxicam and aspirin (Bianchine et al), 247
Genetic polymorphism of phenformin 4-hydroxylation (Oates et al), 81
Gentamicin, unidirectional absorption of, from the peritoneum during continuous ambulatory peritoneal dialysis (Somani et al), 113
Glucocorticoids, reversal of lymphocyte beta-adrenoceptor desensitization of (Hui et al), 566

H

Heart failure, chronic congestive, captopril kinetics in (Cody et al), 721
severe, central hemodynamic effects of dipyridamole in: comparison with hydralazine (Packer et al), 54
Hemodynamic effects of the antiarrhythmic drug pirmenol (Phillips et al), 235
central, of dipyridamole in severe heart failure: comparison with hydralazine (Packer et al), 54
of nitroprusside and furosemide in left ventricular failure (Franciosa et al), 62
Heparin, relationship between concentration and anticoagulant effect of in plasma of hospitalized patients: magnitude and predictability of interindividual differences (Whitfield et al), 503
Hepatic elimination of midazolam, physiologic and temporal variation in (Klotz and Ziegler), 107
microsomal enzyme function, changes in, in workers exposed to mixtures of chemicals (Døssing), 340
Hospitalized patients, plasma of, relationship between concentration and anticoagulant effect of heparin in: magnitude and predictability of interindividual differences (Whitfield et al), 503
HPLC assay, application of a new, for nicotine and its metabolites: smoking-induced changes in nicotine disposition (Kyerematen et al), 769
Hydralazine, comparison with: central hemodynamic effects of dipyridamole in severe heart failure (Packer et al), 54
and furosemide kinetics (Nomura et al), 303

Hydrochlorothiazide and captopril, responses to, in black patients with hypertension (Moser and Lunn), 307
Hydroxylation, microsomal, as measured by pentobarbital elimination in patients with idiopathic systemic lupus erythematosis (Drayer et al), 195
Hypertension, adolescent, effectiveness of centrally acting drugs and diuretics in (Falkner et al), 577
black patients with, responses to captopril and hydrochlorothiazide in (Moser and Lunn), 307
effects of enalapril, a new converting enzyme inhibitor, in (Ferguson et al), 48
severe, treatment of with intravenous labetolol (Papademetriou et al), 431
Hypertensive patients, effects of indoramin and propranolol on cardiovascular response to cold in (Velasco et al), 7
receiving beta-adrenoceptor–blocking drugs, renal effects of acute calcium blockade with nifedipine in (Christensen et al), 572
sotalol prolongation of QT_c interval in (Neuvonen et al), 25
Hyperthyroidism, lymphocyte beta-adrenergic receptors are not altered in (Hui et al), 161
Hypotensive effect, pharmacologic reversal of, complicating antiarrhythmic therapy with bretylium (Woosley et al), 313

I

Idiopathic systemic lupus erythematosis, patients with, microsomal hydroxylation as measured by pentobarbital elimination in (Drayer et al), 195
Imipramine and trazodone, hemodynamic responses of (Hames et al), 497
Indians, Kutchin Athapaskan, drug-plasma protein binding in (Abel et al), 436
Individualized anticoagulation, evaluation of a computer-assisted method for: retrospective and prospective studies with a pharmacodynamic model (Abbrecht et al), 129
Indomethacin delivery systems, kinetics of osmotically controlled after repeated dosing (Bayne et al), 270
effect of, on responses to [sar^1-$ileu^8$]-angiotension II (Fujita et al), 366
Indoramin and propranolol, effects of, on cardiovascular response to cold in hypertensive patients (Velasco et al), 7
Intravenous amiodarone, effect of, on myocardial repolarization and refractoriness: a new method of assessment (Donaldson and Rickards), 727
and oral verapamil dosing, comparison of (Reiter et al), 711
Ioxaglate acid (USAN list No. 229), 541
meglumine (USAN list No. 229), 540
sodium (USAN list No. 229), 540
Iron, controlled-release, absorption of (Cook et al), 531
Isoniazid and rifampicin, effect of, on vitamin D metabolism (Brodie et al), 525

K

Kinetics: *see* specific drug name
Kutchin Athapaskan Indians, drug-plasma protein binding in (Abel et al), 436

L

Labetolol, treatment of severe hypertension with intravenous (Papademetriou et al), 431
Linogliride fumarate (USAN list No. 231), 790
Lipoproteins, significance of, in serum binding variations of amitriptyline, nortriptyline, and quinidine (Pike et al), 599
Lorazepam and buspirone actions, effects of alcohol on (Seppälä et al), 201
Lupus erythematosis, idiopathic systemic, patients with, microsomal hydroxylation as measured by pentobarbital elimination in (Drayer et al), 195
Lymphocyte beta-adrenoceptor desensitization of glucocorticoids, reversal of human (Hui et al), 566
beta-adrenergic receptors are not altered in hyperthyroidism (Hui et al), 161

M

Mebrofenin (USAN list No. 226), 137
Mefenidil (USAN list No. 231), 789
Metabolite(s) of clomipramine, hydroxylated, plasma steady-state concentrations of (Linnoila et al), 208
elimination: nortriptyline metabolism in chronic renal failure (Dawling et al), 322
formation, antipyrine, influence of sex and oral contraceptive steroids on (Teunissen et al), 240
nicotine and its, application of a new HPLC assay for: smoking-induced changes in nicotine disposition (Kyerematen et al), 769
Methadone plasma protein binding: alterations in cancer and displacement from $alpha_1$-acid glycoprotein (Abramson), 652
Methyl palmoxirate (USAN list No. 231), 790
Methyldopa and propranolol, single and repeated doses, biochemical and dynamic responses to during dynamic physical activity (Rosenthal et al), 701
Methylprednisolone elimination, dose- and time-related effect of troleandomycin on (Szefler et al), 166
Metolazone therapy of active calcium nephrolithiasis (Cunningham et al), 642

Microsomal enzyme function, hepatic, changes in, in workers exposed to mixtures of chemicals (Døssing), 340
Midazolam hydrochloride (USAN list No. 227), 277
physiologic and temporal variation in the hepatic elimination of (Klotz and Ziegler), 107
Moxalactam, disulfiram-like activity of (Elenbaas et al), 347
Myocardial infarction, acute, patients with, peripheral arterial and venous responses to acetylstrophanthidin in (Creager et al), 736
repolarization and refractoriness, effects of intravenous amiodarone on: a new method of assessment (Donaldson and Rickards), 727

N

Nalbuphine and codeine, oral, analgesic effects of in patients with postoperative pain (Okun), 517
Nephrolithiasis, active, calcium, metolazone therapy of (Cunningham et al), 642
Nephrotic syndrome, disposition and diuretic effect of furosemide in (Keller et al), 442
Nicotine, cigarette, does it affect puff volume? (Gust and Pickens), 418
concentrations, blood, circadian, during cigarette smoking (Benowitz et al), 758
disposition, smoking-induced changes in: application of a new HPLC assay for nicotine and its metabolites (Kyerematen et al), 769
Nifedipine, effect of, on digoxin kinetics in healthy subjects (Pedersen et al), 562
renal effects of acute calcium blockade with, in hypertensive patients receiving beta-adrenoceptor–blocking drugs (Christensen et al), 572
Nitroprusside and furosemide, hemodynamic effects of, in left ventricular failure (Franciosa et al), 62
Nonselective and cardioselective beta-adrenergic antagonists, effects of on pulmonary mechanics (Foley et al), 149
Nonsmokers and smokers, codeine disposition in (Rogers et al), 218
dose response and route of *N*-demethylation in: caffeine CO_2 breath test (Kotake et al), 261
Nortriptyline and amitriptyline, protein binding variations of (Pike and Skuterud), 228
and quinidine, significance of lipoproteins in serum binding variations of (Pike et al), 599
formation after single oral and intravenous doses of intravenous doses of amitriptyline (Mellström et al), 664
metabolism in chronic renal failure: metabolite elimination (Dawling et al), 322

O

Obsolete problem drug: phenmetrazine (Mellar and Hollister), 671
Oral contraceptive steroids and sex, influence of, on antipyrine metabolite formation (Teunissen et al), 240
dose, effective, and pirmenol kinetics (Hammill et al), 686
and intravenous verapamil dosing, comparison of (Reiter et al), 711
Origin and acquisition of drug candidates, 1963-1979, with analysis of new drug development by United States pharmaceutical firms (Wardell et al), 407
Osmotically controlled indomethacin delivery systems, kinetics of, after repeated dosing (Bayne et al), 270
Oxyfilcon A (USAN list No. 226), 138

P

Pain, postoperative, patients with, analgesic effects of oral nalbuphine and codeine in (Okun), 517
quantification of: an analysis of words used to describe pain and analgesia in clinical trials (Sriwatanakul et al), 143
Palmoxirate sodium (USAN list No. 231), 790
Parkinson's disease, the use of pergolide, a potent dopamine agonist, in (Lieberman et al), 70
Pediatric patients, procainamide elimination kinetics in (Singh et al), 607
Pentobarbital elimination, microsomal hydroxylation as measured by, in patients with systemic idiopathic lupus erythematosis (Drayer et al), 195
Pergolide, a potent dopamine agonist, use of in Parkinson's disease (Lieberman et al), 70
Peripheral arterial and venous responses to acetylstrophanthidin in patients with acute myocardial infarction (Creager et al), 736
Peritoneal dialysis, continuous ambulatory, unidirectional absorption of gentamicin from the peritoneum during (Somani et al), 113
Peritoneum, unidirectional absorption of gentamicin from the, during continuous ambulatory peritoneal dialysis (Somani et al), 113
pH, urine, and phencyclidine excretion (Perez-Reyes et al), 635
Pharmaceutical firms, United States, new drug development by, with analysis of trends in the acquisition and origin of drug candidates, 1963-1979 (Wardell et al), 407
Phencyclidine excretion, urine pH and (Perez-Reyes et al), 635
Phenformin 4-hydroxylation, genetic polymorphism of (Oates et al), 81
Phenmetrazine: an obsolete problem drug (Mellar and Hollister), 671

Phenobarbital, phenytoin, clonazepam, and diazepam, arterial and venous concentrations of, after rapid intravenous injection (Bøjolm et al), 478
Phenol sulfotransferase activity, platelet: correlation with sulfate conjugation of acetaminophen (Reiter and Weinshilboum), 612
Phenytoin, phenobarbital, clonazepam, and diazepam, arterial and venous concentrations of, after rapid intravenous injection (Bøjolm et al), 478
urine and plasma free concentration, correlation of (Casto et al), 628
Pheochromocytoma, prazosin and propranolol in preoperative management of (Cubeddu et al), 156
Physical activity, biochemical and dynamic responses to single and repeated doses of methyldopa and propranolol during (Rosenthal et al), 701
dynamic, dynamic and biochemical responses to single and repeated doses of clonidine during (Lowenthal et al), 18
Physiologic and temporal variation in hepatic elimination of midazolam (Klotz and Ziegler), 107
Pindolol, effects of, on renal function II. effects of intravenous and prolonged oral dosing (Boner et al), 423
Pirlimycin hydrochloride (USAN list No. 230), 668
Pirmenol, hemodynamic effects of the antiarrhythmic drug (Phillips et al), 235
kinetics and effective oral dose (Hammill et al), 686
Piroxicam, aspirin, and gastrointestinal blood loss (Bianchine et al), 247
Plasma binding variations of amitriptyline and nortriptyline (Pike and Skuterud), 228
and cerebrospinal fluid kinetics, cyclophosphamide, with and without dimethyl sulfoxide (Egorin et al), 122
concentration(s) of alpha$_1$-acid glycoprotein and propranolol binding, effects of cancer and its treatments on (Abramson et al), 659
beta blockade, and propranolol dosage (Mullane et al), 692
bioavailability, and beta blockade: timolol and propranolol (Wilson et al), 676
steady-state verapamil, prediction of in children and adults (Wagner et al), 172
drug binding, altered, in cancer: role of α_1-acid glycoprotein and albumin (Jackson et al), 295
free and urine phenytoin concentration correlation (Casto et al), 628
level and renal excretion, digitoxin, cytostatic drugs are without significant effect on (Kuhlmann et al), 646
protein binding, drug-, in Kutchin Athapaskan Indians (Abel et al), 436
Plasma protein binding—cont'd
methadone: alterations in cancer and displacement from α_1-acid glycoprotein (Abramson), 652
steady-state concentrations of hydroxylated metabolites of clomipramine (Linnoila et al), 208
steroid levels, digoxin does not alter, in healthy men (Kley et al), 12
Platelet(s), human, alpha$_2$-adrenoceptor on, lack of interaction between tricyclic antidepressants and clonidine at the (Barnes et al), 744
phenol sulfotransferase activity: correlation with sulfate conjugation of acetaminophen (Reiter and Weinshilboum), 612
Polymorphism, genetic, of phenformin 4-hydroxylation (Oates et al), 81
Postoperative pain, patients with, analgesic effects of oral nalbuphine and codeine in (Okun), 517
PPG-15 stearyl ether (USAN list No. 231), 789
Pramiracetam hydrochloride (USAN list No. 227), 277
sulfate (USAN list No. 227), 277
Prazosin and propranolol in preoperative mangement of pheochromocytoma (Cubeddu et al), 156
α-receptor function after first dose of (von Bahr et al), 41
Pressor dose response, analysis of (Sumner et al), 450
Probenecid, effect of: renal handling of captopril (Singhvi et al), 182
Procainamide elimination kinetics in pediatric patients (Singh et al), 607
Propranolol analog, quarternary, antiarrhythmic effects of, that does not induce beta-adrenergic blockade (Reele et al), 33
binding and plasma concentration of alpha$_1$-acid glycoprotein, effects of cancer and its treatments on (Abramson et al), 659
dosage, plasma concentration, and beta blockade (Mullane et al), 692
and indoramin, effects of, on cardiovascular response to cold in hypertensive patients (Velasco et al), 7
and methyldopa, single and repeated doses, biochemical and dynamic responses to during dynamic physical activity (Rosenthal et al), 701
and prazosin in preoperative management of pheochromocytoma (Cubeddu et al), 156
steady-state kinetics and dynamics of, effects of cimetidine and ranitidine on (Reimann et al), 749
and timolol: bioavailability, plasma concentrations, and beta blockade (Wilson et al), 676

Prostaglandin E levels, synovial fluid, and tolmetin kinetics in rheumatoid arthritis (Dromgoole et al), 371
Protein binding, decreased, and thiopental kinetics (Burch and Stanski), 212
drug-plasma, in Kutchin Athapaskan Indians (Abel et al), 436
plasma, methadone: alterations in cancer and displacement from alpha$_1$-acid glycoprotein (Abramson), 652
theophylline serum, factors influencing (Shaw et al), 490
Psychomotor effects and kinetics in elderly women: diphenhydramine (Berlinger et al), 387
Puff volume, does cigarette nicotine affect? (Gust and Pickens), 418
Pulmonary mechanics, effects of cardioselective and nonselective beta-adrenergic antagonists on (Foley et al), 149

Q

QT_c interval, sotalol prolongation of, in hypertensive patients (Neuvonen et al), 25
Quantification of pain: an analysis of words used to describe pain and analgesia in clinical trials (Sriwatanakul et al), 143
Quarternary propranolol analog, antiarrhythmic effects of, that does not induce beta-adrenergic blockade (Reele et al), 33
Quazepam and flurazepam: long-term use and extended withdrawal (Kales et al), 781
Quinidine, amitriptyline, and nortriptyline, significance of lipoproteins in serum binding variations of (Pike et al), 599

R

Racemic warfarin–ticrynafen interaction: hepatotoxic or stereoselective? (O'Reilly), 356
Ranitidine and cimetidine, clinical comparison of (Brater et al), 484
effects of, on steady-state propranolol kinetics and dynamics (Reimann et al), 749
Receptor(s), α-, function changes after first dose of prazosin (von Bahr et al), 41
lymphocyte beta-adrenergic, are not altered in hyperthyroidism (Hui et al), 161
Refractoriness and repolarization, myocardial, effects of intravenous amiodarone on: a new method of assessment (Donaldson and Rickards), 727
Renal effects of acute calcium blockade with nifedipine in hypertensive patients receiving beta-adrenoceptor–blocking drugs (Christensen et al), 572
excretion and plasma level, digitoxin, cytostatic drugs are without significant effect on (Kuhlmann et al), 646
failure, chronic, nortriptyline metabolism in: metabolite elimination (Dawling et al), 322
Renal—cont'd
function, effects of pindolol on II. effects of intravenous and prolonged oral dosing (Boner et al), 423
handling of captopril: effect of probenecid (Singhvi et al), 182
impairment, benoxaprofen kinetics in (Aronoff et al), 190
Renin-aldosterone blockade by enalapril, an angiotensin-converting enzyme inhibitor, temporal enhancement of (Griffing et al), 592
secretion, basal and furosemide-stimulated, canrenoate reversal of inhibitory effects of digoxin on (Finotti and Antonello), 1
Repolarization and refractoriness, myocardial, effects of intravenous amiodarone on: a new method of assessment (Donaldson and Rickards), 727
Rheumatoid arthritis, tolmetin kinetics and synovial fluid prostaglandin E levels in (Dromgoole et al), 371
Rifampicin and isoniazid, effect of, on vitamin D metabolism (Brodie et al), 525

S

Saliva cortisol levels, effects of cigarettes on (Cherek et al), 765
[Sar^1-ileu^8]-angiotensin II, effect of indomethacin on responses to (Fujita et al), 366
Septal thickness, ventricular, during diuretic therapy (Drayer et al), 283
Serum binding variations, significance of lipoproteins in, of amitriptyline, nortriptyline, and quinidine (Pike et al), 599
protein binding, theophylline, factors influencing (Shaw et al), 490
Sex and oral contraceptive steroids, influence of, on antipyrine metabolite formation (Teunissen et al), 240
Slow-acting furosemide and furosemide, kinetics and dynamics of (Beerman), 584
Smokers and nonsmokers, codeine disposition in (Rogers et al), 218
dose response and route of *N*-demethylation in: caffeine CO_2 breath test (Kotake et al), 261
Smoking behavior and tobacco smoke intake: response of smokers to shortened cigarettes (Chait and Griffiths), 90
cigarette, circadian blood nicotine concentrations during (Benowitz et al), 758
effects of increasing urinary pH on (Cherek et al), 253
free-base cocaine (Perez-Reyes et al), 459
-induced changes in nicotine disposition: application of a new HPLC assay for nicotine and its metabolites (Kyerematen et al), 769
Sotatol prolongation of the QT_c interval in hypertensive patients (Neuvonen et al), 25

Steady-state concentrations, plasma, of hydroxylated metabolites of clomipramine (Linnoila et al), 208
propranolol kinetics and dynamics, effects of cimetidine and ranitidine on (Reimann et al), 749
verapamil plasma concentrations, prediction of in children and adults (Wagner et al), 172
Steroid levels, plasma, digoxin does not alter in healthy men (Kley et al), 12
Sulfate conjugation of acetaminophen, correlation with: platelet phenol sulfotransferase activity (Reiter and Weinshilboum), 612
Sulfotranferase activity, platelet phenol: correlation with sulfate conjugation of acetaminophen (Reiter and Weinshilboum), 612
Sulindac disposition when given once and twice daily (Swanson et al), 397
Synovial fluid prostaglandin E levels and tolmetin kinetics in rheumatoid arthritis (Dromgoole et al), 371

T

Temporal and physiologic variation in hepatic elimination of midazolam (Klotz and Ziegler), 107
Terconazole (USAN list No. 227), 228
Theophylline serum protein binding, factors influencing (Shaw et al), 490
Thiopental kinetics, decreased protein binding and (Burch and Stanski), 212
Thymopentin (USAN list No. 226), 138
Tiaramide hydrochloride (USAN list No. 227), 228
Tiazofurin (USAN list No. 230), 668
Ticrynafen–racemic warfarin interaction: hepatotoxic or stereoselective? (O'Reilly), 356
Time- and dose-related effect of troleandomycin on methylprednisolone elimination (Szefler et al), 166
Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade (Wilson et al), 676
Tobacco smoke intake, smoking behavior and: response of smokers to shortened cigarettes (Chait and Griffiths), 90
Tolmetin kinetics and synovial fluid prostaglandin E levels in rheumatoid arthritis (Dromgoole et al), 371
Trazodone and imipramine, hemodynamic responses of (Hames et al), 497
Triciribine phosphate (USAN list No. 228), 404
Tricyclic antidepressants and clonidine, lack of interaction between, at the alpha$_2$-adrenoceptor on human platelets (Barnes et al), 744
Troleandomycin, dose- and time-related effect of, on methylprednisolone elimination (Szefler et al), 166

U

Unidirectional absorption of gentamicin from the peritoneum during continuous ambulatory peritoneal dialysis (Somani et al), 113
Urinary kinetics, cisplatin, circadian time dependence of (Hrushesky et al), 330
pH, effects of increasing, on cigarette smoking (Cherek et al), 253
Urine pH and phencyclidine excretion (Perez-Reyes et al), 635
and plasma free phenytoin concentration correlation (Casto et al), 628

V

Venous and arterial concentrations of phenobarbital, phenytoin, clonazepam, and diazepam after rapid intravenous injection (Bøjolm et al), 478
responses, peripheral, to acetylstrophanthidin in patients with acute myocardial infarction (Creager et al), 736
Ventilatory response to carbon dioxide, ineffectiveness of beta-adrenergic blockers on (Twum-Barima et al), 289
Ventricular arrhythmias, complex, suppression of, by oral flecainide (Duran et al), 554
failure, left, hemodynamic effects of nitroprusside and furosemide in (Franciosa et al), 62
septal thickness during diuretic therapy (Drayer et al), 283
Verapamil dosing, intravenous and oral, comparison of (Reiter et al), 711
plasma concentrations, steady-state, prediction of in children and adults (Wagner et al), 172
Vitamin D metabolism, effect of rifampicin and isoniazid on (Brodie et al), 525

W

Warfarin, racemic–ticrynafen interaction: hepatotoxic or stereoselective? (O'Reilly), 356
Withdrawal, extended, and long-term use: quazepam and flurazepam (Kales et al), 781
Women, elderly, kinetics and psychomotor effects of diphenhydramine in (Berlinger et al), 387
Workers exposed to mixtures of chemicals, changes in hepatic microsomal enzyme function in (Døssing), 340

X

Xenbucin (USAN list No. 228), 405